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SUMMARY
Renal cell carcinomas (RCCs) are refractory to standard therapies. The von Hippel-Lindau (VHL) tumor sup-
pressor gene is inactivated in 75% of RCCs. By screening for small molecules selectively targeting VHL-de-
ficient RCC cells, we identified STF-62247. STF-62247 induces cytotoxicity and reduces tumor growth
of VHL-deficient RCC cells compared to genetically matched cells with wild-type VHL. STF-62247-stimulated
toxicity occurs in a HIF-independent manner through autophagy. Reduction of protein levels of essential au-
tophagy pathway components reduces sensitivity of VHL-deficient cells to STF-62247. Using a yeast deletion
pool, we show that loss of proteins involved in Golgi trafficking increases killing by STF-62247. Thus, we have
found a small molecule that selectively induces cell death in VHL-deficient cells, representing a paradigm
shift for targeted therapy.INTRODUCTION
Mutations and/or inactivation of the von Hippel-Lindau (VHL)
tumor suppressor gene occur in themajority of renal cell carcino-
mas (RCCs) of the clear cell phenotype. Restoration of VHL func-
tion in VHL/ RCCs results in significant inhibition of tumor
formation by these cells in nude mice, demonstrating the tumor
suppressor function of VHL (Iliopoulos et al., 1995). Functional
studies indicate that pVHL, the protein product of VHL, is an
E3 ubiquitin ligase that targets the a subunit of the hypoxia-
inducible factor (HIF) for proteasomal degradation under
normoxia. In the presence of oxygen, hydroxylation on proline
residues 564 and 402 by prolyl hydroxylases (PHDs) marks
HIF-a for recognition and binding with pVHL, leading to degrada-
tion of HIF-a. Under hypoxic conditions, activity of the PHDs
decreases, reducing recognition of HIF-a by pVHL (Chan et al.,
2002; Ivan et al., 2001; Jaakkola et al., 2001). In cells that lack
VHL, stabilized HIF-a binds constitutively expressed HIF-b to
activate the transcription of genes involved in metabolism, an-
giogenesis, invasion and metastasis, and proliferation (Erler
et al., 2006; Gnarra et al., 1996; Iliopoulos et al., 1996; Knebel-90 Cancer Cell 14, 90–102, July 2008 ª2008 Elsevier Inc.mann et al., 1998; Staller et al., 2003). In addition to its role in
HIF regulation, pVHL has been implicated in a variety of HIF-in-
dependent processes including extracellular matrix assembly,
regulation of microtubule stability, polyubiquitination of atypical
protein kinase C (PKC) family members, regulation of fibronectin,
and modulation of RNA polymerase II subunits (Hergovich et al.,
2003; Na et al., 2003; Ohh et al., 1998; Okuda et al., 2001). It has
also been reported that an acidic domain present in the N-termi-
nal region of pVHL contributes to its tumor suppressor function in
a HIF-independent manner and may be relevant for the develop-
ment of VHL-associated malignancies (Lolkema et al., 2005).
Defects in apoptosis that are observed in many solid tumor
cells, including RCCs, increase the resistance of tumor cells
to chemotherapy, radiotherapy, and molecularly targeted thera-
pies. In contrast to apoptosis, autophagy regulates the turnover
of organelles and long-lived proteins to ensure homeostasis.
Under metabolic stress, autophagy is activated and promotes
survival (Mathew et al., 2007). In some cell types, autophagy
can also result in cell death under persistent stress conditions.
Studies have reported a dysregulated level of autophagy in
diverse diseases including neuronal degeneration, infectiousSIGNIFICANCE
Inactivation of the vonHippel-Lindau (VHL) tumor suppressor gene arises in themajority of renal cell carcinomas (RCCs) and
is associated with a high degree of vascularization and poor prognosis. We evaluated the possibility of targeting VHL-de-
ficient cells through a synthetic lethality approach by screening for small molecules that exhibit toxicity to renal cells lacking
VHL. We identified a compound, STF-62247, which was selectively cytotoxic toward VHL-deficient cells in vitro and in vivo.
We demonstrate that STF-62247 induces autophagy and that inhibition of autophagy significantly reduces sensitivity to
STF-62247. Since RCCs are refractory to standard cytotoxic chemotherapies, there is a need for additional chemotherapies.
STF-62247 is a small molecule that exploits the loss of VHL in RCC.
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Targeting VHL-Deficient Cells by a Small Moleculedisease, and cancer (Kondo et al., 2005). Whether autophagy
protects against or causes these diseases is still unclear,
but the regulation of autophagy has promising therapeutic
implications.
Autophagy occurs in all eukaryotic cells from yeast to mam-
mals. In response to a diverse number of stimuli such as starva-
tion, hypoxia, or high temperature, portions of cytoplasm and
organelles are sequestered in a double-membrane vesicle called
an autophagosome. These vesicles undergo maturation by fu-
sion with endosomes and/or lysosomes to become autolyso-
somes, whose contents are degraded by hydrolases (Klionsky
and Emr, 2000). Among autophagy-related genes (ATGs) identi-
fied to regulate this process, beclin 1 (BECN), the mammalian or-
tholog of yeast ATG6, acts as a tumor suppressor gene in mice
and is frequently deleted in human cancers (Aita et al., 1999). In
mammalian cells, BECN forms a complex with the class III family
of phosphatidylinositol 3-kinases (PI3Ks) and localizes at the
trans-Golgi network (TGN) (Kihara et al., 2001). The elongation
of the double membrane involves two ubiquitin-like conjugation
systems: the ATG5-ATG12 complex and the microtubule-asso-
ciated protein light chain 3 (MAP-LC3; ATG8 in yeast). In
unstressed cells, LC3 is present in the cytoplasm, while the lipi-
dated form of LC3 is associated with double-membrane-con-
taining organelles in cells undergoing autophagy (Kabeya et al.,
2000). The recruitment of LC3 to the membrane occurs in an
ATG5-dependent manner. While ATG5-ATG12 dissociate from
the membrane upon completion of autophagosome formation,
LC3 remains associated with the membrane (Kabeya et al.,
2000; Mizushima et al., 2001). ATG7 acts as an E1 enzyme in
the autophagy conjugation system, where, in combination with
an E2 enzyme, it conjugates phosphatidylethanolamine to
LC3-I to form LC3-II, and no lipidation of LC3 occurs in the brain
of Atg7-deficient mice (Tanida et al., 2002). On the other hand,
ATG9 has been reported to cycle between the TGN and endo-
somes, and its disruption impairs formation of autophagosomes
(Young et al., 2006).
Cell-based small-molecule screening has been used to iden-
tify compounds that inhibit specific proteins, such as HIF, or to
overcome drug resistance to reduce tumorigenicity (Isaacs
et al., 2002; Mabjeesh et al., 2003; Rapisarda et al., 2002;
Smukste et al., 2006). In this report, we describe a small mole-
cule identified from a screen, STF-62247, that induces autoph-
agy and selectively induces lethality in RCCs that have lost the
VHL tumor suppressor gene. We further use a yeast deletion
pool to functionally investigate the targets of STF-62247 that
are involved in cell killing.
RESULTS
STF-62247 Induces Cytotoxicity and Reduces Tumor
Growth in VHL-Deficient Cells in a HIF-Independent
Manner
In this study, we evaluated the possibility of selectively targeting
VHL-deficient cells using small-molecule compounds. We
screened 64,000 compounds against wild-type VHL and VHL-
deficient RCCs (unpublished data) that were stably transfected
with enhanced yellow fluorescent protein (EYFP). The effect of
small molecules on each cell type was monitored separately
by fluorescence (Figure 1A). The drug STF-62247 was identifiedin this screen (see Figure S1A available online) and decreased
the viability of VHL-deficient cells in a short-term assay (Figure-
S1B). Moreover, STF-62247 specifically results in cytotoxicity in
renal cells that have lost VHL as demonstrated using two genetic
models: VHL-deficient RCC4 cells and their counterparts that
express ectopically introduced wild-type VHL, and VHL-profi-
cient SN12C cells and their counterparts that stably express
shRNA targeting VHL (Thomas et al., 2006). Clonogenic assays
demonstrated that STF-62247 is selectively toxic to VHL-defi-
cient cells compared to their wild-type VHL counterparts
(Figure 1B).
Since VHL is an important negative regulator of HIF-a through
its E3 ligase activity, we used VHL-null RCC4 cells expressing
shRNA against HIF-1a or HIF-2a to determine whether STF-
62247 cytotoxicity is dependent on HIF (Figure 1C, bottom
panel). The level of HIF target genes was quantified by qRT-
PCR, verifying functional knockdown of HIF (Figure S1C). Clono-
genic assays demonstrated that the reduction of either HIF-1a or
HIF-2a in VHL-null cells did not affect cell death induced by STF-
62247 (Figure 1C, upper panel). Also, decreasing the level of
ARNT (HIF-1b) using shRNA did not change the cell sensitivity
to STF-62247 (data not shown). Previous studies have indicated
that HIF-2 is critical for tumor growth of RCCs (Kondo et al.,
2003; Zimmer et al., 2004). To further investigate the effect of
HIF-2 in the sensitivity of RCC4 cells to STF-62247, we gener-
ated a VHL cell line that stably expressed a normoxically stable,
constitutively active HIF-2a mutant, P531A N847A. Two individ-
ual HIF-2a RCC4/VHL clones were randomly chosen that had
elevated HIF-2a expression under normoxic conditions
(Figure 1D, bottom panel). The results show that cytotoxicity of
STF-62247 was unaffected by the presence of HIF-2a expres-
sion under normoxic conditions when compared to RCC4/VHL
cells. Thus, by using complementary approaches, our results
indicate that STF-62247 induces cytotoxicity in VHL-null cells
in a HIF-independent manner.
To evaluate the effect of STF-62247 on tumor growth in vivo,
we implanted SN12C, SN12C-VHL shRNA, or 786-O cells sub-
cutaneously into the flanks of immunodeficient mice. The selec-
tive cytotoxicity of STF-62247 for the VHL-deficient cells was
also demonstrated in 786-O cells compared to their wild-type
VHL counterparts by clonogenic assay in vitro (Figure S1D). Daily
treatment with STF-62247 significantly reduced tumor growth of
VHL-deficient cells (Figure 1E). This decrease in tumor growth
was concentration dependent. Importantly, drug treatment did
not have any effect on the growth of SN12C tumor cells that
have wild-type VHL (Figure S1E). Together, these results show
that STF-62247 selectively kills RCC cells with a loss of VHL
in vitro and also significantly reduces tumor growth in cells
deficient in VHL.
Autophagy Is Induced by STF-62247 Treatment
We found that STF-62247 did not induce apoptosis in vitro
in VHL-deficient cells as assayed by Hoechst staining
(Figure S1F), annexin V staining (Figure S1G), or caspase-3 im-
munoblot (Figure S1H). These results were further confirmed by
immunostaining for caspase-3 in tumor sections (Figure S1I).
There was no difference in proliferation as assayed by Ki67 stain-
ing in response to STF-62247 in RCCs deficient in VHL or with
wild-type VHL (Figure S1J). STF-62247 did not induce DNACancer Cell 14, 90–102, July 2008 ª2008 Elsevier Inc. 91
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dition, phosphorylation of p53 on serine 15 and total p53 levels
were unaffected by STF-62247 treatment, further supporting
the lack of a DNA damage signal in cell killing induced by STF-
62247 (Figure S1K). We observed that STF-62247-treated cells
accumulated intracytoplasmic vacuoles characteristic of cells
Figure 1. STF-62247 Induces Cytotoxicity
and Reduces Tumor Growth in VHL-Defi-
cient Cells in a HIF-Independent Manner
(A) RCC4 and RCC4/VHL cells were labeled with
enhanced yellow fluorescent protein (EYFP) and
treated with increasing concentration of STF-
62247 for 4 days. Each cell type was monitored
by fluorescence separately. Cells are pseudocol-
ored green. Scale bar = 10 mm.
(B) Clonogenic assay in RCC4, RCC4/VHL,
SN12C, and SN12C-VHL shRNA cells in the pres-
ence of STF-62247 (0–30 mM). Each point of cell
survival is calculated by the average of three differ-
ent experiments in triplicate as the percent of
treated on untreated plate.
(C) Upper panel: clonogenic assay for RCC4 cells
infected with HIF-1a or HIF-2a shRNA by retroviral
infection in presence of drug in the same condi-
tions described above. Lower panel: HIF-1a or
HIF-2a protein expression evaluated by western
blot in RCC4 cells with HIF-1a or HIF-2a shRNA.
Tubulin was used as loading control.
(D) Upper panel: clonogenic assay with STF-
62247 in VHL-positive RCC4 cells where HIF-2a
was stably introduced by retroviral infection.
Lower panel: western blot for HIF-1a or HIF-2a in
VHL-positive RCC4 cells.
(E) SN12C-VHL shRNA cells (2–3 3 106) and 786-
O cells (5 3 106) were injected into SCID mice.
SN12C-VHL tumor-bearing mice were treated
daily with vehicle or with 2.7 mg/kg or 8 mg/kg
STF-62247 by intraperitoneal injection. 786-O
tumor-bearing mice were treated with vehicle or
8 mg/kg STF-62247. Five tumors per condition
were analyzed. *p < 0.05, **p < 0.01, ***p < 0.005.
All error bars represent standard error of the mean
(SEM).
undergoing autophagy. Moreover, these
vacuoles were larger in VHL-deficient
RCC4 and SN12C-VHL shRNA cells than
inwild-type VHL cells (Figure 2A). Vacuole
formation in RCC cells with and without
VHLwasmonitoredby time-lapsemicros-
copy for 48 hr, which showed that vacu-
oles appear as soon as 3 hr after adding
STF-62247 (Movies S1 and S2). The
time-lapse movies also indicate that
wild-type VHL prevents the formation
of larger vacuoles present in VHL-defi-
cient cells.
Induction of autophagy was confirmed
by immunostaining and western blotting
for LC3. STF-62247 increased punctate
staining of LC3, which is associated with
processing of LC3 to its lipidated form
(Figure 2B). LC3-II, corresponding to the lipidated form found
with the formation of double membranes, was induced by STF-
62247 treatment, indicating that STF-62247 stimulates autoph-
agy (Figure 2D). Transmission electron microscopy was
also used to monitor autophagy in response to STF-62247.
There were large numbers of autophagic vacuoles present in92 Cancer Cell 14, 90–102, July 2008 ª2008 Elsevier Inc.
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The presence of double-membrane-containing cellular organ-
elles was observed in treated RCC4 cells at higher magnification
(Figure S2B).
The increase of the LC3-II form was abrogated by 3-methyla-
denine (3-MA), an autophagy inhibitor that inhibits PI3K. It is
noteworthy that although the stimulation in LC3 was higher in
VHL-deficient cells treated with STF-62247, the increase was
also observed in wild-type VHL cells, and therefore the presence
of autophagosomes cannot by itself explain the difference in tox-
icity observed between RCC cells with and without VHL.We also
stained cells with the autofluorescent compound monodansyl-
cadaverine (MDC), which acts as a lysosomotropic agent and
labels some of the acidic compartments that are observed after
fusion with lysosomes (autolysosomes) (Figure 2C). Staining with
MDC in RCC4 cells was primarily observed around the larger
vacuoles compared to the punctate staining of LC3, suggesting
that these large vacuoles are associated with the acidic compo-
nents of autolysosomes.
Figure 2. Presence of Autophagic Vacuoles
with STF-62247 in Renal Cell Carcinomas
(A) Phase-contrast images of VHL-deficient RCC4
and SN12C-VHL shRNA cells (top) and VHL-posi-
tive RCC4 and SN12C cells (bottom) after 20 hr of
treatment with 1.25 mM STF-62247.
(B) Immunostaining for LC3 following 1.25 mM
STF-62247 treatment for 20 hr with or without 2
mM 3-methyladenine (3-MA) in RCC4 cells with
and without VHL. After treatment, cells were fixed,
permeabilized, and processed for detection of
punctate stainingby indirect immunofluorescence.
(C) Autophagic vacuoles stained with monodan-
sylcadaverine (MDC). After STF-62247 treatment
under the same conditions, MDC was added for
the final 10 min. Cells were fixed, washed with
PBS, and observed directly under a microscope.
(D) Western blot for LC3 in RCC4, RCC4/VHL,
SN12C-VHL shRNA, and SN12C cells after STF-
62247 treatment with or without 3-MA. Nutrient
starvation (EBSS) was used as positive control.
(E) Western blot for LC3 in RCC4 and RCC4/VHL
cells with different concentrations of STF-62247.
Tubulin was used as loading control.
(F) Cell viability assay in VHL-deficient RCC4
and wild-type VHL cells treated with 1 mM 3-MA,
1.25 mM STF-62247, or both for 24 hr. Viability
was measured by trypan blue exclusion assay
and is represented by the average of three different
experiments in duplicate as the percent of treated
on untreated cells. Error bars represent SEM.
All scale bars = 10 mm.
Since autophagy might be an early re-
sponse during drug treatment, LC3 pro-
cessing was monitored in cells exposed
to increasing concentrations of drug.
The results show that the LC3-lipidated
form increased in a concentration-depen-
dent manner, indicating that the autopha-
gic process is tightly linked with drug
cytotoxicity (Figure 2E). To determine
whether autophagy induced by STF-62247 was responsible for
the reduced viability observed in VHL-deficient cells, we mea-
sured the viability after 24 hr of cells treated with 3-MA to inhibit
autophagy. The viability of VHL-deficient cells was partially re-
stored by 3-MA, indicating that STF-62247-induced autophagy
leads to cell death in VHL-deficient cells (Figure 2F).
ATG5, ATG7, and ATG9 Are Involved in Autophagosome
Formation in STF-62247-Treated Cells
Wehypothesized that if autophagy is important in STF-62247 cy-
totoxicity of VHL-deficient cells, Atg5/ cells would be less sen-
sitive to STF-62247-induced cell death. We found significantly
more autophagic vacuoles during STF-62247 treatment in
Atg5+/+ cells compared to Atg5/ cells (Figure 3A). This effect
correlates with the LC3 processing that was observed only in
Atg5+/+ cells in response to STF-62247 and was concentration
dependent (Figure 3B). Importantly, we confirmed that ATG5 is
involved in STF-62247-induced toxicity in VHL-deficient RCC
cells. Silencing ATG5 in VHL-deficient RCC4 cells by siRNACancer Cell 14, 90–102, July 2008 ª2008 Elsevier Inc. 93
Cancer Cell
Targeting VHL-Deficient Cells by a Small MoleculeFigure 3. ATG5 Is Involved in STF-62247 Autophagic Cell Death
(A) Atg5+/+ and Atg5/ murine embryonic fibroblasts (MEFs) were treated in presence of STF-62247 and examined under light microscopy 20 hr later. Scale
bar = 10 mm.
(B) LC3 processing evaluated by western blot following 24 hr of drug treatment in MEFs.94 Cancer Cell 14, 90–102, July 2008 ª2008 Elsevier Inc.
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genic assay (Figure 3C). VHL-positive RCC4 cells were unaf-
fected by ATG5 siRNA, suggesting that the cell death observed
at higher concentrations in VHL-positive cells is independent of
ATG5 and autophagy. A reduction in ATG5-ATG12 levels by
siRNA decreased LC3 formation by STF-62247, indicating a crit-
ical role for ATG5 in the STF-62247 autophagic response in VHL-
deficient RCC cells (Figure 3D). Consistent with a role of the
autophagy pathway in STF-62247 cytotoxicity, reduction of
ATG7 and ATG9 levels by siRNA also reduced the STF-62247
cytotoxicity in VHL-deficient RCC4 cells, although to a lesser
degree (Figure 3F). Similar results were obtained using
VHL-deficient RCC10 and RCC10 cells expressing wild-type
VHL (Figure 3G).
PI3KandGolgi TraffickingAreRequired as Initial Signals
in STF-62247-Induced Autophagy
Previous studies have implicated PI3K and extracellular signal-
regulated kinase (ERK) signaling as well as Golgi trafficking
and endoplasmic reticulum (ER) stress in autophagy (Ogata
et al., 2006; Yorimitsu et al., 2006). To evaluate a role for PI3K
in response to STF-62247, we compared the effects of the
autophagy inhibitor 3-MA to LY294002, another PI3K inhibitor.
LY294002 significantly decreased large vacuole formation and
the LC3-lipidated form in VHL-deficient cells during STF-62247
treatment to a level similar to 3-MA (Figures 4A and 4B; Fig-
ure 2D), indicating a role for PI3K in STF-62247 signaling. In con-
trast, themitogen-activated protein kinase kinase (MEK) inhibitor
U0126, which inhibits ERK activation, had little effect on autoph-
agy induced by STF-62247 (Figures S3A and S3B), indicating
that MEK signaling is not involved in STF-62247-induced
autophagy.
Furthermore, we found that brefeldin A (BFA), a blocker of pro-
tein transport from the ER to the Golgi apparatus, abolished the
formation of autophagic vacuoles and LC3-II stimulated by STF-
62247 in VHL-deficient RCC cells. This suggests that Golgi traf-
ficking is involved in the cytotoxicity of STF-62247 in cells that
have lost VHL (Figures 4A–4C). In contrast, no vacuole or LC3
processing was observed with tunicamycin treatment alone, al-
though it induced BiP (Grp78), a marker of ER stress (Figures
S3A and S3C). Taken together, our results suggest that Golgi
trafficking and PI3K are part of the initial signal for the induction
of autophagy in RCC cells treated with STF-62247.
STF-62247 Increases Acidification
in VHL-Deficient Cells
Although autophagosome formation in response to STF-62247 is
independent of VHL status, we investigated how STF-62247
specifically kills cells that have lost VHL. A late step in the auto-
phagic cell death process is the fusion of lysosomes with auto-phagosomes into autolysosomes, which can be detected by
measuring their acidification with acridine orange staining. Inter-
estingly, we found that acridine orange staining was significantly
increased in VHL-deficient RCC4 cells compared to their wild-
type VHL counterparts (Figure 4D). This observation was quanti-
fied and confirmed by fluorescence-activated cell sorting (FACS)
analyses and illustrates a significant difference in the acidifica-
tion of the acidic vesicular organelles (AVOs) in RCC4 and
SN12C-VHL shRNA cells (Figures 4E and 4F; Figures S3D and
S3E) compared to wild-type VHL cells. Blocking autophagy
with 3-MA or BFA resulted in a decrease in autolysosomal acid-
ification, demonstrating that acidification induced by STF-62247
is linked to the autophagic pathway. In addition, MDC staining
performed using NH4Cl to block vesicle acidification attenuated
the functional staining following drug treatment (Figure S3F).
However, even if the acidification level in VHL cells increases fol-
lowing STF-62247 treatment, this level of acidification remained
significantly lower than in VHL-deficient cells. These results sug-
gest that the fusion of autophagosomes with lysosomes is a key
step leading to autophagic cell death in VHL-deficient cells.
Structure-Activity Studies
Based on the STF-62247 structure, other compounds were
designed and synthesized to evaluate their ability to induce
selective cell death in VHL-deficient cells. Analysis of the high-
throughput screening data indicated a specific requirement for
a 4-pyridyl unit linked to the 4-position of the thiazole, whereas
3-pyridyl analogs were inactive. The requirement of a thiazole
NH suggests an H bond contact in this region. Substituents at
the 2-position on the aryl ring were not tolerated. With these con-
straints inmind, we prepared a focused set of 19 analogs of STF-
62247 to probe structure-activity relationships (Table S1). The
IC50 for these analogs shows that STF-62247 has the lowest
IC50 in VHL-deficient RCC4 cells and the highest IC50 ratio
(VHL/VHL-deficient cells). The compound 30603 with a methyl
group in the 4-position also has a high ratio, but also a higher
IC50 for both RCC4 and RCC4/VHL cells. The IC50 could not be
determined for some compounds because of poor solubility.
To associate the cytotoxicity of these compounds with au-
tophagy, vacuole formation and LC3 processing were evaluated
(Figures 5A and 5B). Compounds with an IC50 ratio VHL/VHL-de-
ficient cells > 5 correlated positively with the presence of large
vacuoles in VHL-deficient cells and the processing of LC3. As
observed with STF-62247 treatment, the LC3-lipidated form
was present in both wild-type VHL and VHL-deficient cell lines.
To confirm that the cell death observed in VHL-deficient cells
was associated with the acidification of autophagic vesicles,
the level of AVOs was measured in response to five analogs
(Figure 5C). The amount of AVOs was consistently higher in
VHL-deficient cells treated with compounds 30603, 31184, and(C) Cell survival measured by clonogenic assay with STF-62247 in RCC4 and RCC4/VHL cells transiently transfected with siRNA against ATG5. Colony formation
was evaluated as described in Figure 1B. ***p < 0.005 between RCC4 and RCC4 with siATG5 in the presence of STF-62247.
(D) mRNA levels of ATG5 quantified by qRT-PCR in RCC4 and RCC4/VHL cells transfected with siRNA against ATG5 for 48 hr.
(E) Western blot for LC3 and ATG5 in RCC4 and RCC4/VHL cells transiently transfected with siRNA against ATG5. Tubulin was used as loading control.
(F and G) Left and middle panels: clonogenic assay with STF-62247 in cells transfected with ATG7 and ATG9 siRNA in VHL-deficient RCC4 (F) and RCC10 (G)
cells andwild-type VHL cells. Colony formation was evaluated as described in Figure 1B. **p < 0.01 between siControl (siCTL) cells and siATG cells in response to
STF-62247. Right panels: mRNA levels ofATG7 andATG9 (andATG5 in RCC10 cells) quantified by qRT-PCR after 48 hr of transfection using siRNA againstATG7
and ATG9 (and ATG5 in RCC10 cells) in RCC4 (F) and RCC10 (G) cells with or without VHL.
All error bars represent SEM.Cancer Cell 14, 90–102, July 2008 ª2008 Elsevier Inc. 95
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Treatment
(A) VHL-deficient RCC4 and wild-type VHL cells were incubated in presence of 10 mM LY294002 or 1 mg/ml brefeldin A (BFA) with 1.25 mM STF-62247 for 20 hr,
and the presence of vacuoles was examined by light microscopy.
(B andC) LC3 processingwas evaluated bywestern blot after treatment with brefeldin A or LY294002 in the presence or absence of STF-62247. Tubulin was used
as loading control.
(D) Cells were treated with 1.25 mM STF-62247 with or without 2 mM 3-MA or 1 mg/ml brefeldin A for 20 hr. For the last 15 min, acidic components were stained
with 1 mg/ml acridine orange and visualized by fluorescence microscopy.
(E) Fluorescence-activated cell sorting (FACS) analysis measuring acidic vesicular organelles (AVOs) in cells treated in (D). The y axis represents the concentrated
red dye in the acidic vesicles, whereas the x axis represents green fluorescence in the cytoplasm and nucleus.
(F) Quantification of the FACS analysis. The data are calculated as the average of three different experiments as relative units of treated over untreated cells.
All error bars represent SEM. All scale bars = 10 mm.30651, which had relatively low IC50 and induced significant vac-
uole formation and the LC3-lipidated form. In contrast, AVO
staining was not influenced in response to compound 3118596 Cancer Cell 14, 90–102, July 2008 ª2008 Elsevier Inc.and 31270, which induced neither autophagy nor cytotoxicity.
These results confirm that the autophagic cell death observed
in VHL-deficient cells is dependent on the acidification of the
Cancer Cell
Targeting VHL-Deficient Cells by a Small MoleculeFigure 5. Evaluation of Autophagy in Renal Cell Carcinomas Treated with Analogs of STF-62247
(A) RCC4 and RCC4/VHL cells were treated with a 1.25 mM concentration of each of 19 analogs for 20 hr, and the presence of vacuoles was examined by light
microscopy. Scale bars = 10 mm.
(B) Western blot for LC3 after treatment with each compound. Tubulin was used as loading control. ‘‘Ratio’’ is the IC50 in RCC4/VHL cells relative to the IC50 in
RCC4 cells.
(C) AVOs measured by FACS analysis in cells treated with 1.25 mM STF-62247 or with compounds 30603, 30651, 31184, 31270, and 31185 and stained with
acridine orange. Error bars represent SEM.vacuoles. The strong relationship between autophagic cell death
and vacuole acidification might explain why autophagy leads to
cell death in VHL-deficient cells and not in wild-type cells.
Use of a Yeast Deletion Pool to Identify Targets
of STF-62247
To identify a target for STF-62247, we performed a screen of
a yeast deletion pool to determine which genes affect STF-
62247 sensitivity. We found that cells lacking proteins involved
in Golgi trafficking and in morphogenesis were most sensitive
to STF-62247 (Table S2). To validate the data obtained from
this screen, we evaluated the sensitivity of eight yeast deletionstrains following STF-62247 treatment (Figure 6A). The killing
curves for the CLA4, VPS20, ALG5, OSH3, and YPT31 deletion
strains show significant toxicity in response to STF-62247. The
ATG8 deletion strain did not exhibit sensitivity to STF-62247 as
expected based on our human ATG studies (data not shown).
The human orthologs known for CLA4, VPS20, ALG5, OSH3,
and YPT31 are PAK2, CHMP6, ALG5, OSBPL3, and RAB11A,
respectively. In mammalian cells, we found that the expression
of ALG5, OSBPL3, and CHMP6 correlated with VHL status
(Figure 6B). These three proteins play a role in coordinating
vesicular transport between the ER, the TGN, and lysosomes.
Moreover, the knockdown of these proteins using siRNACancer Cell 14, 90–102, July 2008 ª2008 Elsevier Inc. 97
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for STF-62247
(A) Killing curves for eight yeast deletion strains. Wild-type (WT),CLA4, VPS20,
VPS25, YPT31, ALG5, APS1, DRS2, and OSH3 were incubated with STF-
62247 (0–100 mM) for 1 hr, and colony formation was evaluated after 2 days.
Each point of survival is calculated by the average of two different experiments
in triplicate as the percent of treated on untreated plate.
(B) qRT-PCR for CHMP6, PAK2, RAB11a, OSBPL3, and ALG5 in RCC4 and
RCC4/VHL cells. The histogram is calculated by the average of three different
experiments in triplicate as the percent of RCC4/VHL on RCC4 cells. Error bars
represent SEM.
(C) VHL cells were transiently transfected with siRNA for CHMP6, OSBPL3,
and ALG5 for 72 hr. For the last 24 hr, 1.25 mM STF-62247 was added, and
vacuole formation was examined by light microscopy. Scale bar = 10 mm.
(D) Clonogenic assay with STF-62247 (0–30 mM) in RCC4/VHL cells transiently
transfected in the same conditions as in (C). Colony formation was evaluated
as described in Figure 1B. Error bars represent SEM. *p < 0.05 between VHL
cells and VHL cells with siRNA in presence of 5 mM STF-62247.
(E) Representative schema of the effect of STF-62247 in renal cell carcinomas
through autophagy. STF-62247 disrupts ER-Golgi trafficking through CHMP6,
OSBPL3, and ALG5 and induces autophagy. Lipidation of LC3 associated with
the double membrane of the autophagosome is observed in an ATG5-depen-
dent manner. Higher acidification of autolysosomes is associated with auto-
phagic cell death in VHL-deficient cells, whereas wild-type VHL cells are
protected against acidification and survive. Regulation of CHMP6, OSBPL3,
and ALG5 proteins by VHL is also observed and remains to be investigated.98 Cancer Cell 14, 90–102, July 2008 ª2008 Elsevier Inc.(Figure S4) increased vacuole formation in response to STF-
62247 (Figure 6C) and cytotoxicity in VHL cells, suggesting
that their loss partially phenocopies the loss of VHL
(Figure 6D). Taken together, our results demonstrate that the
TGN is a target of STF-62247 and a drug-selective pathway
synthetically lethal in VHL-deficient cells.
DISCUSSION
Targeting HIF in cancer therapy is being investigated ardently.
Different screening approaches have identified drugs, cytotoxins
or small molecules, as HIF inhibitors. It has been reported that
radiation in combination with a HIF inhibitor could improve con-
ventional therapies (Moeller et al., 2005). In RCCs with constitu-
tively elevated levels of HIF, different agents that can disrupt or
attenuate the HIF pathway or the protein products of HIF target
genes are presently in clinical trials or have been approved by the
US Food and Drug Administration (FDA). For example, temsiro-
limus (CCI-779) and everolimus (RAD001) inhibit HIF through
the targeting of mTOR. In contrast, agents with antiangiogenic
activity that inhibit vascular endothelial growth factor receptor
(VEGFR) and platelet-derived growth factor receptor (PDGFR)
signaling (e.g., sorafenib and sunitinib), the VEGF ligand (bevaci-
zumab), and the epidermal growth factor (EGF) ligand (cetuxi-
mab) have also shown some effectiveness in the management
of RCC to different degrees (Patel et al., 2006; Sosman et al.,
2007). These agents have all been reported to have antitumor
effects on kidney tumors, but tumors ultimately progress regard-
less of these therapies, as they are not cytotoxic but cytostatic.
In the kidney, the inactivation of the tumor suppressor gene VHL
is an early event that promotes tumorigenesis, leading to clear
cell RCC. We hypothesized that inactivation of VHL in RCC pro-
gression could be therapeutically exploited using a screening
strategy that targets cells with loss of VHL.While different agents
have been used to target the HIF pathway, we investigated an
approach of using small molecules to induce selective cell death
in RCCs that lack a functional VHL gene, the mammalian equiv-
alent of a yeast synthetic lethal screen. Among the drugs identi-
fied from this screen (unpublished data), we found that STF-
62247 was cytotoxic to VHL-deficient cells. Surprisingly, cell
death induced by STF-62247 was independent of HIF-1a or
HIF-2a and was unaffected by hypoxia (data not shown). Our re-
sults support other reports demonstrating that in addition to its
well-understood role in HIF degradation, VHL has other critical
targets that also play important roles in cellular homeostasis
(Hergovich et al., 2003; Lolkema et al., 2005; Na et al., 2003;
Ohh et al., 1998; Okuda et al., 2001).
It has been proposed that the resistance of RCCs to chemo-
therapy and radiotherapy is due to increased levels of nuclear
factor kB (NF-kB) activity and resistance to apoptosis (An
et al., 2005; Oya et al., 2001; Qi and Ohh, 2003). Previous studies
have reported that the metabolic stress observed in human tu-
mors leads cancer cells to acquire resistance to apoptosis and
to stimulate autophagy to maintain energy demand and prevent
necrosis (Jin et al., 2007). Increasing evidence implicates a role
for autophagy in cancer, but it is still not well understood how
cellular and environmental cues drive autophagic cells down sur-
vival or death pathways (Jin et al., 2007; Mathew et al., 2007).
It has been reported that above a certain threshold that destroys
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is induced (Gozuacik and Kimchi, 2007). It is also possible that
autophagy can kill by selective degradation of vital proteins in
the cell. Anticancer therapies using radiation or agents such as
tamoxifen, rapamycin, imatinib, arsenic trioxide, resveratrol, or
soybean B group saponins have recently been reported to
induce autophagic cell death (Bursch et al., 1996; Ellington
et al., 2005; Ertmer et al., 2007; Ito et al., 2005; Kanzawa et al.,
2003; Opipari et al., 2004; Takeuchi et al., 2005). We provide
evidence that STF-62247 induces autophagy and that inhibition
of autophagy significantly increases the survival of VHL-deficient
cells treated with STF-62247.
Among different stimuli, signaling cascades, and proteins that
have been reported to be involved in the initial signal for autoph-
agy, ER stress and Golgi trafficking have been identified in the
formation of autophagosomes (Ogata et al., 2006; Yorimitsu
et al., 2006; Young et al., 2006). The PI3K-beclin 1 (ATG6) com-
plex (Furuya et al., 2005), the PI3K/AKT/mTOR cascade (Takeu-
chi et al., 2005), the Ras/MEK/ERK pathway (Corcelle et al.,
2006), and the p53/p73 family (Crighton et al., 2006, 2007)
have also been found to regulate the autophagic process.
Thus, it appears that the upstream signals that induce autophagy
are stimulus and organism dependent. In our study, we show
that the Golgi trafficking and PI3K pathways are involved in the
STF-62247 upstream signal for autophagosome formation.
More specifically, yeast deletion strains for ALG5, OSH3, and
VPS20 are sensitive to STF-62247. In mammalian cells, knock-
down of the equivalent protein orthologs (ALG5, OSBPL3, and
CHMP6, respectively) that are located in the ER and the TGN
was found to be lethal in combination with STF-62247 in cells
with functional VHL. While knockdown of ALG5, an enzyme
found in the membrane of the ER, sensitizes the cell to death
in cells with functional VHL, ER stress induced by tunicamycin
had no apparent effect in response to STF-62247. ALG5 cata-
lyzes the transfer of glucose from UDP-glucose to dolichyl phos-
phate. A deletion of the yeast ALG5 gene leads to a loss of this
activity and an underglycosylation of carboxypeptidase Y (Hee-
sen et al., 1994). However, the ER stress induced by tunicamycin
that leads to autophagy increases the unfolded protein response
(UPR) and induces the expression of chaperones and proteins
involved in the recovery process (Yorimitsu et al., 2006). ER
stress-induced autophagy has been reported in yeast and in
neuroblastoma but is distinct from autophagy induced by STF-
62247 (Ogata et al., 2006; Yorimitsu et al., 2006). Our results
also show that oxysterol-binding protein-like protein 3
(OSBPL3), a protein involved in a variety of processes such as
secretory vesicle budding from the Golgi and establishment of
cell polarity; the glucosyltransferase ALG5; and CHMP6, a key
component of the endosomal sorting complex required for trans-
port-III (ESCRT-III) required for protein transport into themultive-
sicular body pathway to the lysosomal/vacuolar lumen, are
regulated by VHL (Castro et al., 1999; Perry and Ridgway,
2006; Yorikawa et al., 2005). However, the mechanism of regula-
tion of these proteins by VHL is unknown and remains to be
investigated. Recently, it was reported that disruption of the
ESCRT-III complex induces autophagosome formation and neu-
rodegeneration consistent with our results (Lee et al., 2007). A
role for sterol proteins in elongation of the autophagosomemem-
brane has previously been demonstrated (Nazarko et al., 2007).In addition, STF-62247-induced autophagy was blocked in the
presence of BFA, a compound that causes the TGN to reassem-
ble into extensive tubular processes and merge with the recy-
cling endosomal system. Our results suggest that certain
proteins associated with the TGN and the ER are targeted by
STF-62247 in VHL-deficient RCCs. Furthermore, we show that
ATG9, the only transmembrane ATG, is involved in autophagic
cell death in response to STF-62247. Mammalian ATG9 has
been implicated in trafficking between the Golgi and endo-
somes, supporting a role for the Golgi in the initial signal of
autophagy (Young et al., 2006). Recently, a study reported that
the transcript of sONE, an antisense of eNOS and a yeast homo-
log of ATG9, is upregulated in the absence of VHL function in
a HIF-independent mechanism and may interfere with the
HuR/VHL interaction (Fish et al., 2007).
We established that autophagosome formation occurs in
both VHL-deficient and wild-type VHL cells after STF-62247
treatment. Interestingly, our analyses indicate that the drug
stimulates the maturation of autophagosomes into autolyso-
somes in VHL-deficient cells and that the size of autolyso-
somes is larger in VHL-deficient cells. The acidification present
after fusion with the lysosomes in VHL-inactivated cells was
prevented by treatment with NH4Cl (Figure S3F). Although the
fusion of autophagosomes with lysosomes is known, the mat-
uration steps and proteins implicated remain to be elucidated.
It has been reported that microtubules (Kochl et al., 2006), the
GTPase Rab7 (Gutierrez et al., 2004), and the lysosome-asso-
ciated membrane proteins 1 and 2 (LAMP1 and 2) (Eskelinen
et al., 2002) are essential for the endosome/lysosome fusion
process. Disruption or inactivation of these proteins has been
shown to block the maturation of autophagic vacuoles, likely
before the fusion with the lysosomes. Preliminary results indi-
cate that knockdown of LAMP1 or LAMP2 does not influence
the toxicity of STF-62247 in VHL-deficient cells or in cells
with functional VHL and therefore cannot explain the difference
in acidic vesicular organelles observed. However, our results
suggest that VHL-deficient cells are altered in the autolysoso-
mal maturation step, increasing the acidification of vesicular
organelles.
Many chemotherapeutic agents are limited in their therapeutic
index due to their cytotoxicity to nontumor cells. To develop new
compounds with higher therapeutic indices, targeted genetic
approaches should be considered (Giaccia et al., 2003; Sutphin
et al., 2004). Synthetic lethality describes a combination of
two nonallelic mutations that, although individually nonlethal,
together result in cell death. This concept has been used suc-
cessfully in yeast and Drosophila and shows a potential means
of achieving selective toxicity based on genotypic differences
between tumor cells and normal tissue (Hartman et al., 2001;
Kaelin, 2005). In this study, we found that renal cancer cells de-
ficient in VHL were sensitive to the small molecule STF-62247,
whereas cells with wild-type VHL were unaffected by STF-
62247 treatment, establishing a synthetic lethal situation wherein
both drug treatment and VHL deficiency lead to lethality. We also
identified proteins involved in Golgi trafficking as a targeting
pathway for STF-62247 and demonstrated that STF-62247 in
combination with the loss of VHL leads to synthetic lethality.
This synthetic lethal approach should be considered in the future
for the continued development of other molecular targetingCancer Cell 14, 90–102, July 2008 ª2008 Elsevier Inc. 99
Cancer Cell
Targeting VHL-Deficient Cells by a Small Moleculeagents for the treatment of RCC, as they have the benefit of
selectively killing tumor cells based on their genotype.
EXPERIMENTAL PROCEDURES
Cell Culture and Cell Treatments
RCC4 parental cells and RCC4 cells with VHL reintroduced (RCC4/VHL),
SN12C and SN12C-CSCG-VHL shRNA (gift from George V. Thomas, Univer-
sity of California, Los Angeles), and Atg5+/+ and Atg5/ murine embryonic
fibroblasts (MEFs) (gift from Noboru Mizushima, Tokyo Medical and Dental
University) were maintained in DMEM supplemented with 10% FCS. Cells
were plated at 70% confluency and treated with 1.25 mM (RCC4) or 3.75 mM
(SN12C) STF-62247 overnight in presence or absence of 2 mM 3-MA, 1 mg/ml
brefeldin A, 10 mM LY294002, 2 mg/ml tunicamycin, or 10 mM U0126 (Sigma
Chemical Co.).
Cell Viability Assays
For cell viability assays, 100,000 cells were plated in a 12-well plate. The follow-
ing day, 1.25 mM STF-62247 was added in the presence or absence of 1 mM
3-MA for 24 hr at 37C. Cells were trypsinized and counted by trypan blue
exclusion. For 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-
carboxanilide (XTT) assays, 5,000 RCC4 cells with and without VHL or 2,500
SN12Ccellswith andwithout VHL shRNAwere plated in 96-well plates. The fol-
lowing day, vehicle (DMSO), STF-62247, or each of 19 analogs were added to
media by serial dilution. Four days later, themediawere aspirated, and XTT so-
lution containing 0.3mg/ml of XTT (SigmaChemical Co.) in phenol red-freeme-
dia, 20%FCS, and 2.65mg/ml N-methyl dibenzopyrazinemethyl sulfate (PMS)
was added to the cells and incubated at 37C for 1–2 hr. Metabolism of XTT
was quantified by measuring the absorbance at 450 nm on a plate reader.
Clonogenic Cell Survival Assay
RCC4, RCC4/VHL, SN12C, and SN12C-VHL shRNA cells were plated at 300
cells per 60 mm tissue culture dish. The following day, vehicle or STF-62247
was added, and cells were incubated in the presence of drug for 10 days for
RCC4 and RCC4/VHL and 7–10 days for SN12C and SN12C-VHL shRNA.
The colonies were stained with crystal violet and quantified. Each experiment
was performed at least three times in triplicate.
Western Blot Analysis
After treatments, cells were lysed in urea buffer (9 M urea, 75 mM Tris [pH 7.5],
150 mM b-mercaptoethanol), placed on ice for 10 min, and sonicated briefly
(15 s). Extracts were centrifuged at 8000 3 g for 10 min to eliminate insoluble
material. Lysates were quantitated using Bio-Rad Protein Assay, and 20–30 mg
quantities of proteins were separated on 7.5%or 15%bis-acrylamide gels and
then transferred onto PVDF membranes. Proteins were visualized using HIF-
2a (Novus Biological), HIF-1a, pVHL, and BiP (BD Biosciences), LC3 (MBL),
Atg5 (gift from N. Mizushima), or a-tubulin antibodies.
Quantification of Acidic Vesicle Organelles with Acridine Orange
In acridine orange-stained cells, the cytoplasm and nucleus are bright green
and dim red whereas acidic compartments are bright red. The intensity of
the red fluorescence is proportional to the degree of acidity. Following 20 hr
of treatment with STF-62247 or analogs, cells were stained with 1 mg/ml of ac-
ridine orange for 15 min. Cells were trypsinized and then analyzed by flow cy-
tometry using a FACScan cytometer (BDBiosciences) andCellQuest software.
Immunofluorescence Staining
Cells were seeded on glass coverslips, and STF-62247 was added at subcon-
fluence at 1.25 mM for RCC4 and 3.75 mM for SN12C. After 20 hr, cells were
fixed in 3.7% formaldehyde for 10 min at room temperature and washed in
PBS. Cells were then permeabilized in 0.2% Triton X-100 for 5 min at room
temperature and washed in PBS. The coverslips were incubated with primary
LC3 antibody diluted 1:500 in PBS containing 0.2% BSA for 1 hr at room tem-
perature. Cells were washed three times in PBS-BSA, and the bound primary
antibody was detected using a fluorescein-conjugated secondary antibody
(Alexa 488) diluted 1:500 in PBS-BSA and incubated for 1 hr. Coverslips
were washed andmounted inmountingmedium (Vector Laboratories) accord-100 Cancer Cell 14, 90–102, July 2008 ª2008 Elsevier Inc.ing to the manufacturer’s instructions. Cells were examined with a confocal
microscope.
Visualization of MDC Vacuoles
Cell were incubated in the presence of drug for 20 hr and labeled with a 50mM
concentration of the autofluorescent marker monodansylcadaverine (MDC)
(Sigma Chemical Co.) in PBS at 37C for 10 min. Cells were then fixed with
3.7% formaldehyde for 10 min at room temperature and washed in PBS.
MDC was observed by fluorescence microscopy with a Nikon Eclipse E800.
In Vivo Studies
All animal experiments were performed in accordance with institutional and
national guidelines and approved by Stanford University’s Administrative
Panel on Laboratory Animal Care (APLAC). Male SCID mice, 4 to 6 weeks
old, were obtained from either Stanford University’s Research Animal Facility
or Charles River Laboratories. SN12C (2–33 106), SN12C-VHL shRNA (2–33
106), or 786-O (5 3 106) cells were resuspended in sterile PBS and injected
subcutaneously. Mice were randomized into vehicle control group or treat-
ment group and treated daily by intraperitoneal injection. When tumors
reached 100 mm3, mice in the treatment group implanted with SN12C or
SN12C-VHL shRNA cells were treated with 8 mg/kg or 2.7 mg/kg of STF-
62247, whereas 2 weeks after 786-O cell implantation, mice were treated
with 8 mg/kg of STF-62247. Tumor growth wasmeasured every 2–3 days after
drug treatment was started.
shRNA Constructs, Plasmids, and Retroviral Infection
The CMV-EYFP fluorescent protein and the HIF-2a P531A N847A double
mutant were cloned into pBabe-puro vector. The sequences used for HIF-
1a and HIF-2a shRNA were GAGGAACTACCATTATAT and GGAGACG
GAGGTGGTCTAT, respectively. Retroviruses were produced by transfecting
plasmids into VNX amphotropic cell lines according to the manufacturer’s in-
structions with Lipofectamine Plus (Invitrogen). The next day after transfection,
cells were placed at 32C. Retroviruses were harvested 48 and 72 hr after
transfection. Puromycin was used to select for stable retroviral integrants.
Transient Transfection of RCCs
Cells were transfected with siRNA against ATG5, CHMP6, PAK2, RAB11a,
OSBPL3, ALG5, ATG7, ATG9 (SMARTpool), and siControl2 nontargeting
pool from Dharmacon using Dharmafect reagent 1 for 48 hr. Cells were split
for clonogenic assay and harvested for RNA or protein.
Screen in Yeast and Killing Curves
Genotypes of the parental yeast strain BY4743, construction of the homozy-
gous diploid deletion strains, and construction of the homozygous diploid
deletion pool were as described previously (Thomas et al., 2006). A mutant
pool of 4728 nonessential homozygous diploid deletion strains was used.
The parental diploid strain BY4743 was used as a control in survival and
complementation assays. For clonogenic survival, equivalent numbers of early
log-phase parental and deletion strains for ALG5, APS1, OSH3, CLA4, DRS2,
DAP1, VPS20, VPS25, FIG4, and SPT4 were suspended in yeast extract pep-
tone dextrose (YPD) and treated with STF-62247 (0–100 mM) for 1 hr while
being shaken at 300 rpm at 30C. Cells were then pelleted, washed once
with buffer (10 mM Tris, 5 mM EDTA), pelleted, and resuspended in the
same buffer. Cells were then plated at appropriate dilutions onto YPD solid
medium to allow for accurate counting of surviving colonies (range 50–250).
Plateswere incubated for 2 days at 30Cbefore counting colonies. Full survival
curves were performed in triplicate for each selected deletion strain.
Quantitative RT-PCR
RNA from cells transfected with siControl or siAtg was prepared using TRIzol
(Invitrogen) according to the manufacturer’s protocol. Reverse transcription
(RT) was performed with Moloney murine leukemia virus (MMLV) reverse tran-
scriptase (Invitrogen) using 2 mg of RNA and 5 mM random primers (Invitrogen)
according to the manufacturer’s instructions. Approximately 0.5% of each RT
reaction was used for quantitative RT-PCR reactions containing 5 ml 23 SYBR
greenmaster mix (ABI) and 200 nM forward and reverse primers specific to the
different genes of interest in a volume of 10 ml. Detection and data analysis
were carried out with an ABI PRISM 7900 sequence detection system using
Cancer Cell
Targeting VHL-Deficient Cells by a Small MoleculeTBP primers as an internal control. PCR primer sequences were obtained from
the Primer Bank database (http://pga.mgh.harvard.edu/primerbank/), and
primers were synthesized in the Stanford Protein and Nucleic Acid Biotechnol-
ogy Facility.
SUPPLEMENTAL DATA
The Supplemental Data include two tables, four figures, and two movies and
can be found with this article online at http://www.cancercell.org/cgi/
content/full/14/1/90/DC1/.
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